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Abstract
Background: Malignant neoplasia of the adrenal cortex is usually associated with very poor
prognosis. When adrenocortical neoplasms are diagnosed in the early stages, distinction between
carcinoma and adenoma can be very difficult to accomplish, since there is yet no reliable marker
to predict tumor recurrence or dissemination. GATA transcription factors play an essential role in
the developmental control of cell fate, cell proliferation and differentiation, organ morphogenesis,
and tissue-specific gene expression. Normal mouse adrenal cortex expresses GATA-6 while its
malignant counterpart only expresses GATA-4. The goal of the present study was to assess
whether this reciprocal change in the expression of GATA factors might be relevant for predicting
the prognosis of human adrenocortical neoplasms. Since human adrenal cortices express luteinizing
hormone (LH/hCG) receptor and the gonadotropins are known to up-regulate GATA-4 in gonadal
tumor cell lines, we also studied the expression of LH/hCG receptor.
Methods: We conducted a study on 13 non-metastasizing (NM) and 10 metastasizing/recurrent
(MR) tumors obtained from a group of twenty-two adult and pediatric patients. The expression of
GATA-4, GATA-6, and LH/hCG receptor (LHR) in normal and tumoral human adrenal cortices
was analysed using reverse transcriptase-polymerase chain reaction (RT-PCR) complemented by
dot blot hybridization.
Results: Messenger RNA for GATA-6 was detected in normal adrenal tissue, as well as in the
totality of NM and MR tumors. GATA-4, by its turn, was detected in normal adrenal tissue, in 11
out of 13 NM tumors, and in 9 of the 10 MR tumors, with larger amounts of mRNA found among
those presenting aggressive clinical behavior. Transcripts for LH receptor were observed both in
normal tissue and neoplasms. A more intense LHR transcript accumulation was observed on those
tumors with better clinical outcome.
Conclusion: Our data suggest that the expression of GATA-6 in human adrenal cortex is not
affected by tumorigenesis. GATA-4 expression is more abundant in MR tumors, while NM tumors
express more intensely LHR. Further studies with larger cohorts are needed to test whether
relative expression levels of LHR or GATA-4 might be used as prognosis predictors.
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Background
Malignant neoplasia of the adrenal cortex is a rare patho-
logical condition accounting for 0.05% – 0.2% of all can-
cers [1]. These tumors are usually associated with
unfavorable prognosis. Five-year survival rate of patients
presenting with evidences of adjacent tissue invasion,
lymph node infiltration or metastases is reported to range
between 15 to 25% [2]. Distinction between localized
tumors with malignant behavior and benign adrenocorti-
cal neoplasms, based on clinical presentation and imag-
ing studies, can be difficult [3]. Direct histopathologic
analysis of tumoral samples has been widely accepted as
the best available diagnostic tool to differentiate metasta-
sizing and recurring from non-metastasizing and non-
recurring tumors [3]. The evaluation of combined histo-
logic features and establishment of specific scores, as pro-
posed by Weiss [4], poses, however, some technical
difficulties, even for skilled pathologists. This is particu-
larly true for criteria such as nuclear grade, venous or sinu-
soid invasion, and diffuse architecture [5]. It is usually
difficult to interpret and manage patients with tumors
presenting an intermediate Weiss score of 3, which is con-
sidered a threshold value for malignancy [6]. Although
high mitotic rate and DNA ploidy index may correlate
with poor survival, not a single histopathologic feature
has proven to be a reliable predictor of recurrence and
metastasis [6-8]. Also, Weiss classification tends to be
inaccurate for tumoral behavior prediction in children
[9,10].
In order to provide reliable markers to predict tumoral
outcome, the prognostic relevance of a wide array of
genetic, molecular and immunohistochemical markers
has been tested [2,3,11]. Adrenocortical malignant con-
version has been associated with coordinated changes of
antigen expression profile, such as undetectable levels of
cytokeratins combined with high levels of vimentin [12].
Increased immunostaining index of the Ki67 antigen,
which is a proliferation-associated nuclear protein, and
elevated telomerase activity have also been related to
more unfavorable prognosis [11,13,14].
Chromosomal instability is frequently described in asso-
ciation with tumoral progression. Genetic instabilities
such as gains in chromosome 3, 9 and X, as well as losses
of heterozygosity of 11q13 (MEN-1 locus) [15,16], 17p13
[17,18] and 11p15 [19] have all been reported to be prog-
nostically relevant for adrenocortical malignancy. The
11p15 region harbors genes such as IGF-II, H19, H-ras
and p57KIP2. Overexpression of insulin-like growth factors
I and II (IGF-I and IGF-II, respectively), of IGF-I receptor
and of IGF-binding protein 2 has been implicated in
tumor progression and acquisition of the malignant phe-
notype in adrenal cortex [20,21]. Mutations of the p53
tumor suppressor (TP53) gene have been associated with
hereditary (Li-Fraumeni syndrome) and sporadic adreno-
cortical tumors [22-25]. Unfortunately, none of these
markers has been shown to be consistently reliable, since
both conflicting results and overlaps between benign
adrenal adenomas and carcinomas have been reported
[20-23].
Expression of nuclear transcription factors has been
recently studied, including the cAMP-dependent tran-
scription factors CREM and CREB. Preliminary results,
although limited by the number of cases, suggest that the
lack of expression of CREB and inducible cAMP early
repressors (ICERs) might be linked to a more severe out-
come [26]. The role of members of another family of tran-
scription factors – GATA family – in adrenocortical
tumorigenesis has been assessed. This family of transcrip-
tion factors constitute a group of 6 structurally related zinc
finger proteins, that binds to conserved (A/T)GATA(A/G)
sequences. Based on sequence homology and expression
profile GATA proteins have been classified into two sub-
families: the hematopoietic group and the cardiac group.
The first group comprises GATA-1, GATA-2 and GATA-3,
and are mainly expressed in hematopoietic stem cells. The
second includes GATA-4, GATA-5 and GATA-6, which are
expressed in heart, lung, gut epithelium, liver, yolk sac
endoderm, gonads, adrenal cortex, hypothalamus and
pituitary [27,28]. GATA factors play an essential role in
the developmental control of cell fate, cell proliferation
and differentiation, organ morphogenesis, and tissue-spe-
cific gene expression [29-31]. High GATA-4 expression
has been suggested to promote cell proliferation through
an anti-apoptotic effect in mouse and human granulosa
cells [32]. A decrease in GATA-4 expression is associated
with follicular atresia through programmed cell death
[33]. Various tumors have been associated with high
expression of GATA-4 like granulosa and theca cell tumors
[28], endodermal sinus tumor [34], esophageal/gastric
adenocarcinomas [35], Sertoli and Leydig cell tumors
[36]. Involvement of GATA-4 has been reported in mouse
adrenocortical tumorigenesis [37]. Normal postnatal
mouse adrenals express abundant GATA-6 mRNA, but no
or little GATA-4 [37]. An opposite expression pattern,
however, has been reported in mouse adrenocortical
tumors, where GATA-4 is up-regulated and GATA-6 down-
regulated during tumorigenesis. Using immunohisto-
chemical staining, up-regulation of GATA-4 was also dem-
onstrated in three human adrenocortical carcinomas, but
not in normal adrenal tissue, adenomas or pheochromo-
cytomas [37].
In order to assess whether this change in the pattern of
GATA expression could be used in prognostic prediction
for human adrenocortical neoplasm, we analysed the
expression of GATA-4 and GATA-6 in 13 non-metastasiz-
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ing and 10 metastasizing/recurrent tumors obtained from
22 patients.
Methods
Patients
Tissue specimens were obtained from twenty-two patients
with adrenocortical tumors (Table 1). Most of them has
been followed in our service since the initial diagnosis of
adrenocortical neoplasm. A fraction of these patients were
referred to us after undergoing adrenalectomy. Before sur-
gery, informed consent was obtained from all patients or
their parents. Ages varied from 2 to 46 years at the time of
diagnosis, with 6 males and 16 females. Initial clinical
presentation included Cushing's syndrome, adult female
virilization, adult male feminization, hypertension, pseu-
doprecocious puberty, and only one patient with a non-
functional tumor (Table 1). Based on their clinical
behavior adrenal tumors were classified as nonmetastasiz-
ing (NM) or metastasizing/recurring (MR). Patients
included in the NM group (n = 13) presented no disease
recurrence or metastasis after a mean follow-up of 6.84 ±
1.44 years (Table 1). Conversely, except for patient 22, 9
patients in the MR group died within 1.56 ± 0.79 years
since the initial diagnosis, after presenting tumor dissem-
ination and/or recurrence (Table 1). Patient 22, whose
clinical data have been previously reported [25], pre-
sented two independent tumors excised from both left
and right adrenals in a two-year period. Subsequently sol-
itary lung metastases were detected and surgically treated.
He shows no signs of residual disease after a seven-year
follow-up. A same pathologist reviewed histopathological
data from all patients and, when sufficient data were avail-
able, calculated Weiss scores (Table 1).
RNA extraction and cDNA synthesis
Tumor samples were immediately frozen in liquid nitro-
gen at the time of surgery and stored until RNA extraction.
Total RNA from tumor samples and from human adreno-
cortical NCI-H295A cells was extracted using a guanidin-
ium-thiocyanate-based commercial kit (TRI-Reagent,
Sigma, St. Louis, MO). A commercial preparation of adult
human adrenal total RNA (Human Adrenal Gland Total
RNA, Clontech, Palo Alto, CA) was used as normal con-
trol. Five micrograms of total RNA from each sample were
treated with 0.5 U of DNAse I, (Promega Corp., Madison,
WI) for 30 min at 37°C. DNAse-treated RNAs were
reversely transcribed at 42°C for 75 min with 200 U of a
RNase H- MMLV reverse transcriptase (Superscript II, Life
Technologies Inc. Gaithersburg, MD) in a final volume of
20 µl containing 50 mM Tris-HCl, pH 8.3, 75 mM KCl, 3
mM MgCl2, 1 mM of each dNTP, 100 mM dithiothreitol,
0.5 µg of oligo dT (Life Technologies Inc. Gaithersburg,
MD), and 30 U of RNAse inhibitor (RNasin, Promega
Corp., Madison, WI).
Table 1: Clinical Data of Patients Presenting with Adrenocortical Tumor
Patient Gender Age at Diagnosis (yr) Follow-up (yr) Clinical Presentation Tumor Evolution Weiss Score
01 M 8 7.58 V NM 4
02 M 9 7.58 V NM 4
03 F 44 6.92 C NM 0
04 M 2 3.75 V NM 5
05 F 33 6.42 C NM 0
06 F 29 6.42 C NM 3
07 F 40 7.33 NF NM 1
08 F 4 6 V NM NA
09 F 28 6.42 C NM NA
10 F 27 6.42 H NM NA
11 F 2 8.17 C and V NM 2
12 F 24 5.92 C NM 1
13 F 46 10 C NM 1
14 M 29 1 (†) C MR 8
15 M 30 0.83 (†) F MR NA
16 F 18 1.17 (†) C and V MR 8
17 F 23 2 (†) C and V MR 6
18 F 32 2.33 (†) V MR NA
19 F 29 3 (†) V MR NA
20 F 22 1 (†) C and V MR NA
21 F 9 1.17 (†) C MR 7
22 M 2 6.25 V MR 7
V: androgen-producing, C: glucocorticoid-producing, H: aldosterone-producing, NF: nonfunctioning, F: estrogen-producing, †: deceased, NM: 
non-metastasizing, MR: metastasizing/recurring, NA: insufficient data for Weiss score calculation.
BMC Endocrine Disorders 2004, 4:3 http://www.biomedcentral.com/1472-6823/4/3
Page 4 of 11
(page number not for citation purposes)
Polymerase Chain-Reaction
One tenth of RT products was amplified in a 50 µl reac-
tion mix containing 20 pmol of each specific primer, 0.2
mM dNTP each, 50 mM KCl, 10 mM Tris-HCl (pH 9.3),
1.5 mM MgCl2 and 5 U Taq Polymerase (Amersham-Phar-
macia, Piscataway, NJ). Twenty microliters of the PCR
product were loaded on a 1.5% agarose gel for electro-
phoresis and visualization with ethidium bromide. 194-
bp GATA-4 and 285-bp GATA-6 cDNA fragments were
amplified using oligonucleotides GATA4-F: 5'-TCCCTCT-
TCCCTCCTCAAAT-3', GATA4-R: 5'-TCAGCGTGTAAAG-
GCATCTG-3', GATA6 – F: 5'-
GAGAAGATGGAAGGGAAGGG-3', GATA6-R: 5'-TGTG-
TACCAAATGGCCTCAA-3', designed according to human
GATA-4 and GATA-6 cDNA sequences (GenBank acces-
sion n° D78260 and U66075, respectively). Cycling con-
ditions for PCR were: 95°C, 3 min, followed by 40 cycles
at 95°C, 30 sec, 56°C, 30 sec, 72°C, 30 sec, and a final
extension cycle of 7 min at 72°C. Amplification of a 234
bp fragment from the human luteinizing hormone recep-
tor (LHR) transcript was accomplished using oligonucle-
otides eLHR: 5'-AGACATTCCAAAGAGATTTC-3' and
LHR2101R: 5'-GCAGTTACTGATGTAACAGTTAACAC-3'.
Cycling conditions were essentially the same as those
described for GATA cDNA amplification except for a 50°C
annealing temperature. As we amplified only exonic
sequences, samples were tested with and without reverse
transcriptase in order to rule out genomic DNA contami-
nation. Samples quantity and integrity were verified by
amplification of a 259-bp cyclophilin cDNA fragment
using oligonucleotides CYC-F: 5'-TTTCACAGAAATTAT-
TCCAGGGTTT-3' e CYC-R: 5'-CAATATTCATGCCTTCTT-
TCACTT-3'. Direct sequencing was performed to confirm
the identity of RT-PCR products.
Dot-blot
Fifteen microliters of GATA-4, GATA-6, LHR and cyclophi-
lin PCR products were mixed with 185 µL NaOH 0.4 M,
EDTA 25 mM, heated 95°C for 2 min, and vacuum-trans-
ferred onto a nylon membrane (Hybond N+, Amersham,
Piscataway, NJ). Probes were generated by radioactive
PCR as follows: fragments corresponding to GATA-4,
GATA-6, LHR, and cyclophilin were amplified by PCR
using genomic DNA as template. The amplification condi-
tions and primer sets were the same as those described in
the previous section. These fragments were then cloned
into the pCR2.1-TOPO T.A. cloning vector (TOPO TA
Cloning kit, Invitrogen, Carlsbad, CA). The identity of the
desired cloned inserts was verified by direct sequencing. A
second PCR was performed in a 25 µl reaction mix con-
RT-PCR and dot-blot hybridization for GATA-6, GATA-4, and LHR expression in normal human adrenal and in NCI-H295A cellsFigure 1
RT-PCR and dot-blot hybridization for GATA-6, GATA-4, and LHR expression in normal human adrenal and in NCI-H295A 
cells. Correct sizes for GATA-6 and GATA-4 transcripts are, respectively, 285 and 194 bp. M: 1 kb molecular size ladder Ad: 
normal adrenal. NCI: NCI-H295A cells. +: genomic DNA. -: negative control for RT-PCR.
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taining 100 ng of plasmid (GATA-4-pCR2.1, GATA-6-
pCR2.1, LHR-pCR2.1, and cyclophilin-pCR2.1), 20 pmol
of M13F/R primers, 0.1 mM dNTP each, 50 mM KCl, 10
mM Tris-HCl (pH 9.3), 1.5 mM MgCl2, 0.5 µl of [α-32P]
dCTP (3000 Ci/mmol), and 5 U Taq Polymerase (Amer-
sham-Pharmacia, Piscataway, NJ). Cycling conditions
were: 94°C, 3 min, followed by 30 cycles at 94°C, 30 sec,
55°C, 30 sec, 72°C, 30 sec, and a final extension cycle of
7 min at 72°C. Probes were purified using Quiaquick PCR
Purification kit (Quiaquick PCR Purification kit, Qiagen
GmbH, Germany) after visualization in a 6% polyacrila-
mide gel. The membranes were pre-hybridized in 5 ×
SSPE, 5 × Denhardt's, 1% SDS, 5% dextran, 50% forma-
mide, and ssDNA (200 µg/ml) for two hours at 42°C. The
hybridization was carried out overnight at 42°C in the
same solution after addition of the probes (100 ng).
Membranes were rinsed once in 2 × SSC, 0.1% SDS for 15
min at room temperature and then washed three times in
0.1 × SSC, 0.1% SDS, first at room temperature for 15
min, and twice at 65°C for 30 and 15 min. Membranes
were exposed overnight on a phosphorscreen and an
autoradiography was obtained using a Storm 860 phos-
phorimager (Amersham Pharmacia Biotech, Piscataway,
NJ). Densitometric analysis was carried out using Image-
Expression of GATA-6 in neoplastic human adrenal tissues was evaluated by RT-PCR and dot-blot hybridizationFigure 2
Expression of GATA-6 in neoplastic human adrenal tissues was evaluated by RT-PCR and dot-blot hybridization. RT-PCR 
products were resolved in 2% agarose gels. Tissue samples represented here, as well as in Figures 3–5, correspond to patients 
listed in Table 1. Samples 22a and 22b are tumor specimens removed from left (22a) and right (22b) adrenal of the same 
patient (patient 22, Table 1). M: 1 kb molecular size ladder Ad: normal adrenal. +: genomic DNA. -: negative control for RT-
PCR. Samples 1 to 13: non-metastasizing; samples 14 to 22: metastasizing/recurring adrenocortical tumors.
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Quant 2.1 software (Amersham Pharmacia Biotech, Pis-
cataway, NJ). Two normalizations were performed: 1 –
densitometry data from tumor samples were normalized
using the optical density from respective positive control,
in order to correct any variation in transferring efficiency
and probe activity. 2 – optical densities of GATA-4, GATA-
6 and LHR were normalized for each tumor sample with
corresponding cyclophilin densitometry data in order to
obtain the relative expression levels. Intra and inter-assay
coefficients of variation for GATA-4, GATA-6, and LHR
are, respectively, 4.14% and 13.23%, 12.63% and
12.24%, 7.73% and 12.16%.
Statistical analysis
Relative expression of GATA-6, GATA-4 and LHR in non-
mestasizing and metastasizing groups was compared
using Student t test. The ability of empirically defined cut-
off values of GATA-4, 6 and LHR transcripts to discrimi-
nate between these two groups was verified using Chi-
square test.
Results
Expression of GATA-6 and GATA-4 in human 
adrenocortical neoplasms
The ability of both normal and tumoral human adrenal
cortices and also a human adrenocortical cell line – NCI-
H295A [38,39] – to express GATA-6 and GATA-4 was
assessed by PCR amplification of reversely transcribed
total RNA. In order to enhance the detection sensitivity
and to perform quantitative analysis of GATA-6 and
GATA-4 accumulation, amplification products from a sec-
ond RT-PCR were then vacuum-transferred to a mem-
brane and subjected to dot-blot hybridization. Both
GATA-6 and GATA-4 transcripts were detectable in nor-
mal adrenal and in NCI-H295A cells, with GATA-6 being
more abundant than GATA-4 (Figure 1). Thus, both GATA
transcripts are normally expressed in human adrenal and
NCI-H295A cells. GATA-6 mRNA was detected in all 23
tumors, irrespective of their behavior (Figure 2). Sample
16 yielded no visible amplification product on agarose gel
but was clearly positive for GATA-6 in dot-blot (Figure 2),
Expression of GATA-4 in neoplastic human adrenal tissuesFigure 3
Expression of GATA-4 in neoplastic human adrenal tissues.
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illustrating the higher detection sensitivity of this method.
Amplification product corresponding to GATA-4 cDNA
was detected in 11 out of 13 NM tumors and in 9 of the
10 MR tumors (Figure 3). Although a faint band, with the
expected size for GATA-4, was visible in the lane corre-
sponding to sample 16 (Figure 3), no signal was detected
on dot-blot. Given the higher sensitivity and specificity of
dot-blot, this sample was considered negative and the
band regarded as an artifact. Densitometric analysis of the
autoradiogram provided quantitative information regard-
ing accumulation of GATA transcripts (Table 2). Non-
metastasizing tumors expressed more GATA-6 than
metastasizing ones (respectively, 3.035 ± 0.111 and 2.568
± 0.138, p = 0.032) while an opposite pattern was
observed for GATA-4 (0.539 ± 0.143 and 1.776 ± 0.384, p
= 0.003).
Expression of LH/hCG receptor in human adrenocortical 
neoplasms
Gonadotropins have been shown to up-regulate GATA-4
in gonadal tumor cell lines [30,32]. In mouse Leydig cell
lines, GATA-4 mRNA accumulation is stimulated by hCG
[30]. Since LH/hCG receptor has been detected in both
normal human and tumoral mouse adrenal cortices
[40,41], we speculated that LHR expression might be cor-
related with the accumulation of GATA-4 in human adre-
nal cortex. For this reason, we investigated the expression
pattern of LH receptor in our adrenocortical specimens.
Amplification products of LHR transcript were observed
in all tumors, and also in normal adrenal cortex and NCI
cells (Figures 1 and 4). Samples displaying more abun-
dant LHR transcripts were, in their majority, NM tumors.
Nevertheless, no statistically significant difference in LHR
mRNA accumulation was found (1.298 ± 0.24 and 0.757
± 0.162, respectively for NM and MR groups, p = 0.209) in
this group compared to the MR one. Samples expressing
more abundant GATA-4 generally expressed smaller
amounts of LHR (samples 15, 17, 19, 20, Figures 3, 4 and
6). Conversely, samples expressing smaller amounts of
GATA-4 usually expressed LHR more intensely (samples
2, 5, 7, 8, 11, 13, Figures 3, 4 and 6).
Correlation between tumor behavior and expression of 
GATA-4, 6 and LHR
Since the relative expression of GATA transcripts in the
NM group is different from those in the MR group (Table
2) we examined whether a cut-off value for the expression
of such mRNAs could be used as a predictor of tumor
behavior. In our cohort, an empirically established expres-
sion level of GATA-4 above 1.77 is correlated with poor
Table 2: GATA-6, GATA-4, and LHR expression in human adrenocortical tumors
Patient Tumor Evolution GATA-6 Expression GATA-4 Expression LHR Expression
1 NM 2.43 1.09 0.54
2 NM 3.39 0.60 1.60
3 NM 3.58 1.75 1.60
4 NM 3.45 0.59 1.07
5 NM 3.21 0.05 1.64
6 NM 2.98 0.91 0.69
7 NM 2.59 0 0.83
8 NM 3.19 0.04 1.17
9 NM 2.62 0.70 1.00
10 NM 3.02 0.52 0.54
11 NM 3.45 0.14 3.84
12 NM 2.44 0.62 0.78
13 NM 3.11 0 1.57
14 MR 3.24 0.32 0.41
15 MR 2.30 3.50 0.44
16 MR 1.74 0.01 0.35
17 MR 2.81 2.50 0.41
18 MR 2.14 3.37 1.06
19 MR 2.61 2.17 0.33
20 MR 2.71 2.96 0.50
21 MR 2.83 0.12 0.48
22a MR 3.23 0.58 1.76
22b MR 2.07 2.23 1.83
Patients are identified as in Table 1. Relative expression levels were calculated normalizing optical densities of GATA-6, GATA-4 and LHR 
autoradiograms with corresponding cyclophilin densitometric data as described in materials and methods. Samples 22a and 22b are tumor specimens 
removed from left (22a) and right (22b) adrenal of the same patient (patient 22, Table 1) NM: non-metastasizing, MR: metastasizing/recurring
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prognosis (p = 0.006) with a relative risk of 4.25 (95% CI:
1.508 – 4.25). Such a cut-off value, however, would lead
to a false negative diagnosis of 4 out of 10 MR subjects
(patients 14, 16, 21, and 22a). In contrast, no cut-off
allowing a clear discrimination between favorable and
unfavorable outcome could be determined for GATA-6.
We also verified whether LHR expression could serve as a
predictor for tumor outcome. Although NM and MR
groups showed no differences regarding the relative
expression of LHR, expression below an empirical thresh-
old of 0.53 was correlated with aggressive behavior (p =
0.002) with a relative risk of 5.333 (95% CI: 1.815 –
5.333). Combination of both GATA-4 and LHR did not
improve any further the ability to discriminate tumoral
behavior and clinical fate.
Discussion
In this report, carried out on 22 patients, we demonstrated
that expression of GATA-4 in human adrenal cortex is not
confined to malignant tumors, but also occurs in non-
metastasizing tumors. GATA-6 transcripts were detected
in all tumor samples, regardless of their biological behav-
ior. We believe that the obtained RT-PCR products truly
reflect the actual expression of GATA factors in those tis-
sue samples and are not a result of amplification of GATA
transcripts expressed in the stroma and capillaries sur-
rounding the neoplastic adrenocortical cells. First, we
were able to detect both GATA-6 and 4 transcripts in cul-
tured human adrenal NCI-H295A cells (Figure 1), dem-
onstrating that expression of these two members of the
GATA family actually occurs in some cell lines of human
adrenal cortex. Second, there are a number of unequivo-
Expression of LHR in neoplastic human adrenal tissuesFigure 4
Expression of LHR in neoplastic human adrenal tissues. Expected size for LHR amplification product is 234 bp.
M 1 2 3 4 5 6 7 8 9 10 11 12 13 A
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cally GATA-4 negative tissue specimens among those we
have analyzed in this study (Figure 3), suggesting that the
contribution of GATA-4 from the endothelial cells and
surrounding tumoral stroma on the RT-PCR signal was
negligible.
The highest GATA-4 expression levels are found among
the MR samples. This suggests that a high relative expres-
sion of GATA-4 might be correlated with a poor outcome.
Nevertheless, GATA-4 expression is not confined solely to
malignant neoplasms of human adrenal cortex since 11
out of 13 NM tumors were GATA-4 positive. Our results
are not consistent with a previous study, based on a model
of adrenal tumorigenesis using inhibin α promoter/SV40
Tag transgenic mice, which revealed that GATA-4 was up-
regulated while GATA-6 was down-regulated in carcino-
mas [37]. It is not clear why there were such differences
between our data and those observed in the inhibin α pro-
moter/SV40 Tag transgenic mice [37]. One possible expla-
nation relies on the difference in sensitivity of the
detection method. In this study, we used RT-PCR followed
by dot-blot, which is more sensitive than ribonuclease
protection assay for detection of gene expression. Alterna-
tively, given the probable relationship between the hyper-
secreted gonadotropins and adrenocortical tumorigenesis
on these transgenic mice [41-43], we speculated that the
reciprocal pattern of GATA-6 and 4 expression reported
for this mouse model might be the result of an increased
secretion of LH following gonadectomy.
Expression of cyclophilin in neoplastic human adrenal tissuesFigure 5
Expression of cyclophilin in neoplastic human adrenal tissues. Integrity of total RNA used in RT-PCR experiments was con-
firmed by the presence of a 259 bp cyclophilin cDNA fragment in all tissue samples.
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Tumors expressing higher levels of GATA-4 tended to
exhibit lower levels of LHR, while the opposite has also
occurred. It is worth noting that both tumor samples
removed from patient 22, who presented an unexpectedly
benign evolution (Table 1), expressed the highest levels of
LHR amongst the whole MR group (Table 2). In spite of
presenting recurrent pulmonary metastases, this patient is
presently alive and his disease is under control after surgi-
cal excision of those metastatic lesions. This observation
suggests a possible correlation between long-term survival
and higher expression of LHR. It remains to be confirmed
whether a higher relative expression of LHR is associated
with a less aggressive disease course.
We conclude that, in opposition to experimental mouse
adrenocortical tumors, expression of GATA-6 in human
adrenal cortex is not affected by tumorigenesis, and per-
sists in both metastasizing and non-metastasizing neo-
plasms. In this small series of patients GATA-4 expression
tends to be more intense in metastasizing tumors. Further
studies with larger cohorts are warranted before one can
reach a more definitive conclusion regarding the prognos-
tic value of expression level of LHR or GATA-4 in adreno-
cortical neoplasms.
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